385 related articles for article (PubMed ID: 28068668)
1. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.
Britschgi A; Duss S; Kim S; Couto JP; Brinkhaus H; Koren S; De Silva D; Mertz KD; Kaup D; Varga Z; Voshol H; Vissieres A; Leroy C; Roloff T; Stadler MB; Scheel CH; Miraglia LJ; Orth AP; Bonamy GM; Reddy VA; Bentires-Alj M
Nature; 2017 Jan; 541(7638):541-545. PubMed ID: 28068668
[TBL] [Abstract][Full Text] [Related]
2. Hippo signalling maintains ER expression and ER
Ma S; Wu Z; Yang F; Zhang J; Johnson RL; Rosenfeld MG; Guan KL
Nature; 2021 Mar; 591(7848):E1-E10. PubMed ID: 33658690
[No Abstract] [Full Text] [Related]
3. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
4. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
5. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
6. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER
Ma S; Tang T; Probst G; Konradi A; Jin C; Li F; Gutkind JS; Fu XD; Guan KL
Nat Commun; 2022 Feb; 13(1):1061. PubMed ID: 35217640
[TBL] [Abstract][Full Text] [Related]
8. A Non-Canonical Hippo Pathway Represses the Expression of ΔNp63.
Low-Calle AM; Ghoneima H; Ortega N; Cuibus AM; Katz C; Prives C; Prywes R
Mol Cell Biol; 2024 Jan; 44(1):27-42. PubMed ID: 38270135
[TBL] [Abstract][Full Text] [Related]
9. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
10. RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.
Roßwag S; Sleeman JP; Thaler S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831091
[TBL] [Abstract][Full Text] [Related]
11.
Tsoi M; Morin M; Rico C; Johnson RL; Paquet M; Gévry N; Boerboom D
FASEB J; 2019 Oct; 33(10):10819-10832. PubMed ID: 31268774
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of Lats1 and Lats2 highlights the role of hippo pathway effector YAP in larynx and vocal fold epithelium morphogenesis.
Mohad V; Lungova V; Verheyden J; Thibeault SL
Dev Biol; 2021 May; 473():33-49. PubMed ID: 33515576
[TBL] [Abstract][Full Text] [Related]
13. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
14.
Nantie LB; Young RE; Paltzer WG; Zhang Y; Johnson RL; Verheyden JM; Sun X
Development; 2018 Nov; 145(21):. PubMed ID: 30305289
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
16. LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development.
Lee DH; Park JO; Kim TS; Kim SK; Kim TH; Kim MC; Park GS; Kim JH; Kuninaka S; Olson EN; Saya H; Kim SY; Lee H; Lim DS
Nat Commun; 2016 Jun; 7():11961. PubMed ID: 27358050
[TBL] [Abstract][Full Text] [Related]
17. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
[TBL] [Abstract][Full Text] [Related]
18. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
19. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
20. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
